PATENTSCOPE: EN_ALL:nmr AND PA:(JOHNSON)

PROCESS (Fri, 08 Mar 2019)
Process is disclosed for the hydrogenation of a compound comprising an α,β-unsaturated carbonyl group to form a compound comprising an allyl alcohol group, wherein the hydrogenation is carried out in the presence of a hydrogenation catalyst, hydrogen gas and an inorganic base in an aqueous solvent, wherein the hydrogenation catalyst is an iron-, ruthenium- or osmium-containing complex.
>> Read More

PROCESS (Fri, 08 Mar 2019)
A process is disclosed for the hydrogenation of a compound comprising an α,β-unsaturated carbonyl group to form a compound comprising an allyl alcohol group, wherein the hydrogenation is carried out in the presence of a hydrogenation catalyst, hydrogen gas and an inorganic base in a solvent, wherein the solvent is essentially free of water and the hydrogenation catalyst is an iron-, ruthenium- or osmium-containing complex of Formula (III), (IV), (V) or (VI) as described in the description.
>> Read More

PROCESS (Fri, 11 Jan 2019)
The present invention provides a metallocenyl compound of formula (I). Ra, Rb, Rc, Rd, Re, Rf, M, m, n, j, k, Y and Z and * are as described in the specification. The invention also provides a process for the preparation of the complexes, a process for increasing the optical purity of a compound of formula (II) and a process for the asymmetric transfer hydrogenation (ATH) of a metallocenyl compound of formula (V) to a metallocenyl compound of formula (IV).
>> Read More

NEW QUINOLINONE COMPOUNDS (Fri, 04 Jan 2019)
Provided are new quinolinone compounds, pharmaceutical compositions comprising said compounds, processes for the preparation of said compounds and the use of said compounds as FGFR inhibitors and their use in the treatment of diseases, e.g. cancer.
>> Read More

POLYMERIZABLE BLOCKERS OF HIGH ENERGY LIGHT (Fri, 04 Jan 2019)
Described are high energy light blocking compounds and ophthalmic devices containing the compounds. In particular, described are hydroxybiphenyl benzotriazole structures with polymerizable functionality that block high energy light and are visibly transparent. The hydroxybiphenyl benzotriazole structures can be incorporated into ophthalmic devices, such as hydrogel contact lenses, to protect eyes from high energy light radiation.
>> Read More

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS (Fri, 04 Jan 2019)
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
>> Read More

HYDROXYPHENYL PHENANTHROLINES AS POLYMERIZABLE BLOCKERS OF HIGH ENERGY LIGHT FOR PREPARING OPHTHALMIC DEVICES, SUCH AS E.G. CONTACT LENSES (Fri, 04 Jan 2019)
Described are high energy light blocking compounds and ophthalmic devices containing the compounds. In particular, described are hydroxyphenyl phenanthroline structures with polymerizable functionality that block high energy light and are visibly transparent. The hydroxyphenyl phenanthroline structures can be incorporated into ophthalmic devices, such as hydrogel contact lenses, to protect eyes from high energy light radiation.
>> Read More

A METHOD OF SYNTHESISING A PT(II) COMPLEX; A PT(II) COMPLEX; USE OF SUCH A COMPLEX AS A PHOTOACTIVATABLE CATALYST IN A HYDROSILYLATION REACTION (Fri, 12 Oct 2018)
A method of synthesising a Pt(ll) complex includes a first step of preparing a reaction mixture comprising a water-soluble hexachloroplatinate salt and a compound according to Formula I', or salt thereof, and allowing the water-soluble hexachloroplatinate salt and the compound according to Formula I' to react and a second step of adding a further quantity of the compound according to Formula I', or a salt thereof, to the reaction mixture. Products of this method are Pt(ll) complexes according to Formula I The Pt(ll) complexes are useful as catalysts in hydrosilylation reactions.
>> Read More

NOVEL FORMS OF AFATINIB DIMALEATE (Fri, 12 Oct 2018)
The present disclosure is directed to a crystalline, hydrated form of afatinib dimaleate having about 2 to 3 molecules of water, designated as Form Z, a pharmaceutical composition comprising the form, its method of use for treating a patient, and process for its preparation.
>> Read More

COMPOSITE MATERIAL (Fri, 05 Oct 2018)
A composite material comprises a macroporous silicate-based material at least partially substituted with at least one microporous zeolite, wherein the microporous zeolite is functionalised with either copper, iron or both copper and iron, and wherein the composite material is in the form of particles.The composite material can be obtained using a method comprising the steps of: (i) providing a mixture comprising a silicate-containing scaffold having a macroporous structure, an aluminium source and an organic template; (ii) hydrothermally treating the mixture to form a microporous zeolite-containing structure substantially retaining the macroporous structure of the silicate-containing scaffold; (iii) incorporating copper, iron or both copper and iron into the zeolite. The silicate-containing scaffold can be a diatomaceous earth.
>> Read More

SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS (Fri, 17 Aug 2018)
Potent 5-HT2B antagonist of Formula (A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof and their use wherein R1 to R4 and Ar have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them, alone or in combination with other drugs, in fibrosis and/or cirrhosis prevention or therapy.
>> Read More

PROCESS (Fri, 27 Apr 2018)
The present invention provides a process for the preparation of a complex of formula (I): comprising the step of reacting Pd(diolefin)X2 or PdX2 and PR1 R2R3 in a solvent to form the complex of formula (I), wherein the process is carried out in the absence of a base, the molar ratio of Pd(diolefin)X2 : PR1 R2R3 or PdX2 : PR1 R2R3 is greater than 1 : 1.1, up to about 1 :2.5; each X is independently a halide; and R1, R2 and R3 are independently selected from the group consisting of tert-butyl and isopropyl.
>> Read More

POLYMER COMPOSITIONS CONTAINING GRAFTED POLYMERIC NETWORKS AND PROCESSES FOR THEIR PREPARATION AND USE (Fri, 09 Feb 2018)
Provided are polymer compositions made by a process comprising: (a) providing a first reactive composition containing: (i) a polymerization initiator that is capable, upon a first activation, of forming two or more free radical groups, at least one of which is further activatable by subsequent activation; (ii) one or more ethylenically unsaturated compounds; and (iii) a crosslinker; (b) subjecting the first reactive composition to a first activation step such that the first reactive composition polymerizes therein to form a crosslinked substrate network containing a covalently bound activatable free radical initiator, (c) combining the crosslinked substrate network with a second reactive composition containing one or more ethylenically unsaturated compounds; and (d) activating the covalently bound activatable free radical initiator of the crosslinked substrate network such that the second reactive composition polymerizes therein with the crosslinked substrate network to form a grafted polymeric network and a byproduct polymer. Also provided are precursors to the polymer compositions, processes for preparation of the polymer compositions, and methods of using the polymer compositions, for instance in medical devices.
>> Read More

SUNSCREEN COMPOSITIONS CONTAINING A COMBINATION OF A LINEAR ULTRAVIOLET RADIATION-ABSORBING POLYETHER AND OTHER ULTRAVIOLET-SCREENING COMPOUNDS (Fri, 22 Dec 2017)
Sunscreen composition including a combination of a linear ultraviolet radiation absorbing polyether that includes a covalently bound UV-chromophore, and at least one non-polymeric UV-screening compounds.
>> Read More

STA-19, A NEW MEMBER OF THE GME FAMILY OF MOLECULAR SIEVE ZEOTYPES, METHODS OF PREPARATION AND USE (Fri, 27 Oct 2017)
STA-19, a molecular sieve having a GME structure and phosphorus in the framework, is described. STA-19AP (as prepared) can have a lower alkyl amine, such as trimethylamine, and olig-(1,4-diazabicyclo[2.2.2]octane)-pentyl dibromide ([DABCO-C5]x where x represents the number of repeating units) or olig-(1,4-diazabicyclo[2.2.2] octane)-hexyl dibromide ([DABCO-C6]x)as SDAs. A lower alkyl ammonium hydroxide, such as tetrabutylammonium hydroxide (TBAOH), can be used as a pH modifier for the preparation of SAPO-STA-19. A calcined product, STA-19C, formed from STA-19AP is also described. Methods of preparing STA-19AP, STA-19C and metal containing calcined counterparts of STA-19C are described along with methods of using STA-19C and metal containing calcined counterparts of STA-19C in a variety of processes, such as treating exhaust gases and converting methanol to olefins are described.
>> Read More

METHODS OF PRODUCING SAPO-56, AN AFX-CONTAINING MOLECULAR SIEVE (Fri, 27 Oct 2017)
The invention relates to a method of preparing SAPO-56, (AFX) using a lower alkyl amine, preferably trimethylamine, and a 1,4-diazabicyclo [2.2.2]octane derivative, preferably comprising either 1,4-(1,4-diazabicyclo[2.2.2]octane)butyl cations or 1,5-(1,4- diazabicyclo[2.2.2]octane)pentyl cations, as structure directing agents (SDAs). A lower alkyl ammonium hydroxide, such as tetrabutylammonium hydroxide (TBAOH), can be used to control the pH. The invention also relates to SAPO-56 comprising a lower alkyl amine, such as trimethylamine, and a 1,4-diazabicyclo [2.2.2]octane derivative, such as a compound comprising either 1,4-(1,4-diazabicyclo[2.2.2]octane)butyl cations or 1,5-(1,4- diazabicyclo[2.2.2]octane) pentyl cations.
>> Read More

STA-18, A NEW MEMBER OF THE SFW FAMILY OF MOLECULAR SIEVE ZEOTYPES, METHODS OF PREPARATION AND USE (Fri, 27 Oct 2017)
STA-18, a molecular sieve having a SFW structure and containing phosphorus in the framework, is described. STA-18AP (as prepared) can have a lower alkyl amine, such as trimethylamine, and one of 1,6-(1,4-diazabicyclo[2.2.2]octane)hexyl cations (from diDABCO-C6) or 1,7-(1,4-diazabicyclo[2.2.2]octane)heptyl cations (from diDABCO-C7) or 1,8-(1,4-diazabicyclo[2.2.2]octane)octyl cations (from diDABCO-C8) as SDAs. A lower alkyl ammonium hydroxide, such as tetrabutylammonium hydroxide, can be used as a pH modifier for making SAPO STA-18. A calcined product, STA-18C, formed from STA-18AP is also described. Methods of preparing STA-18AP, STA-18C and metal containing calcined counterparts of STA-18C are described along with methods of using STA-18C and metal containing calcined counterparts of STA-18C in a variety of processes, such as treating exhaust gases and converting methanol to olefins are described.
>> Read More

COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF (Fri, 06 Oct 2017)
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
>> Read More

COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF (Fri, 06 Oct 2017)
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
>> Read More

COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF (Fri, 06 Oct 2017)
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin- related disorders.
>> Read More